Concepts (182)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 15 | 2018 | 105 | 1.850 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 11 | 2016 | 443 | 1.230 |
Why?
|
| Leukemia, Myeloid, Acute | 9 | 2017 | 211 | 1.130 |
Why?
|
| Transplantation Conditioning | 10 | 2018 | 23 | 0.830 |
Why?
|
| Lymphoma, Non-Hodgkin | 5 | 2013 | 28 | 0.700 |
Why?
|
| Amifostine | 3 | 2018 | 5 | 0.670 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2012 | 25 | 0.650 |
Why?
|
| Graft vs Host Disease | 6 | 2015 | 39 | 0.610 |
Why?
|
| Cytoprotection | 3 | 2018 | 9 | 0.560 |
Why?
|
| Stem Cell Transplantation | 6 | 2013 | 221 | 0.550 |
Why?
|
| Lymphoma | 3 | 2016 | 37 | 0.520 |
Why?
|
| Transplantation, Homologous | 8 | 2015 | 158 | 0.480 |
Why?
|
| Transplantation, Autologous | 14 | 2018 | 100 | 0.430 |
Why?
|
| Azacitidine | 1 | 2013 | 27 | 0.400 |
Why?
|
| Sirolimus | 1 | 2013 | 34 | 0.400 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2013 | 106 | 0.380 |
Why?
|
| Remission Induction | 8 | 2018 | 92 | 0.350 |
Why?
|
| Methylprednisolone | 1 | 2011 | 14 | 0.340 |
Why?
|
| Gastrointestinal Tract | 1 | 2011 | 40 | 0.340 |
Why?
|
| Hodgkin Disease | 5 | 2012 | 16 | 0.330 |
Why?
|
| Melphalan | 4 | 2018 | 8 | 0.330 |
Why?
|
| Hematologic Neoplasms | 4 | 2015 | 39 | 0.320 |
Why?
|
| Glucocorticoids | 1 | 2011 | 146 | 0.310 |
Why?
|
| Middle Aged | 21 | 2018 | 11851 | 0.280 |
Why?
|
| Liver | 1 | 2011 | 492 | 0.280 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2010 | 7 | 0.280 |
Why?
|
| Humans | 32 | 2018 | 32282 | 0.260 |
Why?
|
| Adult | 19 | 2018 | 9259 | 0.250 |
Why?
|
| Maximum Tolerated Dose | 4 | 2018 | 62 | 0.240 |
Why?
|
| Aged | 17 | 2018 | 10263 | 0.240 |
Why?
|
| Myeloablative Agonists | 3 | 2015 | 6 | 0.230 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 717 | 0.230 |
Why?
|
| Female | 22 | 2018 | 19945 | 0.230 |
Why?
|
| Leukemia | 1 | 2004 | 38 | 0.210 |
Why?
|
| Antibodies, Monoclonal | 2 | 2009 | 245 | 0.210 |
Why?
|
| Male | 20 | 2018 | 19441 | 0.210 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 140 | 0.200 |
Why?
|
| Multiple Myeloma | 3 | 2018 | 24 | 0.200 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2004 | 89 | 0.200 |
Why?
|
| Hydrazines | 2 | 2013 | 4 | 0.190 |
Why?
|
| Benzoates | 2 | 2013 | 7 | 0.190 |
Why?
|
| Radiation-Protective Agents | 1 | 2002 | 5 | 0.190 |
Why?
|
| Whole-Body Irradiation | 2 | 2013 | 58 | 0.190 |
Why?
|
| Cancer Vaccines | 1 | 2003 | 27 | 0.190 |
Why?
|
| Pyrazoles | 2 | 2013 | 77 | 0.190 |
Why?
|
| Treatment Outcome | 8 | 2018 | 3416 | 0.170 |
Why?
|
| Recurrence | 5 | 2013 | 285 | 0.170 |
Why?
|
| Stem Cells | 1 | 2004 | 321 | 0.170 |
Why?
|
| Combined Modality Therapy | 6 | 2016 | 555 | 0.160 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2011 | 19 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2013 | 381 | 0.160 |
Why?
|
| Neoplasms | 2 | 2008 | 754 | 0.160 |
Why?
|
| Survival Analysis | 6 | 2013 | 477 | 0.150 |
Why?
|
| Cytarabine | 4 | 2016 | 59 | 0.140 |
Why?
|
| Disease-Free Survival | 7 | 2018 | 324 | 0.140 |
Why?
|
| Antineoplastic Agents | 4 | 2011 | 595 | 0.140 |
Why?
|
| Young Adult | 7 | 2016 | 2649 | 0.140 |
Why?
|
| Blood Component Transfusion | 1 | 2017 | 10 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 14 | 0.130 |
Why?
|
| Breast Neoplasms | 1 | 2003 | 762 | 0.120 |
Why?
|
| Prognosis | 5 | 2013 | 1534 | 0.120 |
Why?
|
| Survival Rate | 7 | 2017 | 893 | 0.120 |
Why?
|
| Thrombocytopenia | 2 | 2013 | 30 | 0.120 |
Why?
|
| Stomatitis | 1 | 2015 | 18 | 0.120 |
Why?
|
| Carmustine | 2 | 2016 | 11 | 0.110 |
Why?
|
| Drug Administration Schedule | 2 | 2013 | 276 | 0.110 |
Why?
|
| Drug Administration Routes | 1 | 2013 | 13 | 0.100 |
Why?
|
| Pentostatin | 1 | 2013 | 3 | 0.100 |
Why?
|
| Photopheresis | 1 | 2013 | 2 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 30 | 0.100 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2012 | 1 | 0.090 |
Why?
|
| Follow-Up Studies | 6 | 2016 | 2240 | 0.090 |
Why?
|
| Platelet Transfusion | 1 | 2012 | 15 | 0.090 |
Why?
|
| Receptors, Thrombopoietin | 1 | 2012 | 1 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2015 | 853 | 0.090 |
Why?
|
| Secondary Prevention | 1 | 2012 | 73 | 0.090 |
Why?
|
| Neoplasms, Second Primary | 2 | 2009 | 24 | 0.090 |
Why?
|
| Hemorrhage | 1 | 2012 | 95 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2013 | 553 | 0.090 |
Why?
|
| Injections, Intra-Arterial | 1 | 2011 | 7 | 0.090 |
Why?
|
| Comorbidity | 2 | 2013 | 565 | 0.090 |
Why?
|
| Drug Resistance | 1 | 2011 | 42 | 0.080 |
Why?
|
| Medical Records | 1 | 2011 | 75 | 0.080 |
Why?
|
| Pancytopenia | 1 | 2010 | 5 | 0.080 |
Why?
|
| Mucositis | 1 | 2010 | 10 | 0.080 |
Why?
|
| Etoposide | 1 | 2010 | 38 | 0.080 |
Why?
|
| Infant | 2 | 2011 | 1010 | 0.080 |
Why?
|
| Incidence | 2 | 2015 | 1241 | 0.080 |
Why?
|
| Retrospective Studies | 4 | 2013 | 3626 | 0.080 |
Why?
|
| Child | 3 | 2011 | 2435 | 0.080 |
Why?
|
| Time Factors | 3 | 2009 | 2205 | 0.070 |
Why?
|
| Cell Survival | 2 | 2007 | 288 | 0.070 |
Why?
|
| Salvage Therapy | 4 | 2012 | 135 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2009 | 7 | 0.070 |
Why?
|
| Adolescent | 6 | 2016 | 3519 | 0.070 |
Why?
|
| Piperazines | 1 | 2008 | 60 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2007 | 26 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2007 | 73 | 0.070 |
Why?
|
| Pyrimidines | 1 | 2008 | 77 | 0.070 |
Why?
|
| Health Status | 1 | 2009 | 355 | 0.070 |
Why?
|
| Risk Factors | 2 | 2012 | 3934 | 0.060 |
Why?
|
| Heterocyclic Compounds | 1 | 2007 | 14 | 0.060 |
Why?
|
| Disease Progression | 1 | 2009 | 591 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2009 | 390 | 0.060 |
Why?
|
| Cell Movement | 1 | 2007 | 167 | 0.060 |
Why?
|
| Atrial Fibrillation | 1 | 2010 | 410 | 0.060 |
Why?
|
| Cell Communication | 1 | 2005 | 37 | 0.060 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 68 | 0.060 |
Why?
|
| Apoptosis | 2 | 2005 | 375 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2010 | 823 | 0.060 |
Why?
|
| Leukocyte Transfusion | 1 | 2004 | 3 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2004 | 165 | 0.050 |
Why?
|
| Endothelial Cells | 1 | 2005 | 193 | 0.050 |
Why?
|
| Clinical Trials as Topic | 2 | 2003 | 312 | 0.050 |
Why?
|
| Glycolipids | 1 | 2003 | 1 | 0.050 |
Why?
|
| Injections, Intradermal | 1 | 2003 | 8 | 0.050 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2003 | 8 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2004 | 248 | 0.050 |
Why?
|
| Glycoproteins | 1 | 2003 | 34 | 0.050 |
Why?
|
| Cyclophosphamide | 2 | 2015 | 37 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 215 | 0.050 |
Why?
|
| Neoplasm Metastasis | 1 | 2003 | 222 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2013 | 461 | 0.040 |
Why?
|
| Mice | 2 | 2007 | 2571 | 0.040 |
Why?
|
| Boronic Acids | 2 | 2013 | 9 | 0.040 |
Why?
|
| Pyrazines | 2 | 2013 | 14 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2011 | 76 | 0.040 |
Why?
|
| Podophyllotoxin | 1 | 2016 | 1 | 0.030 |
Why?
|
| Outpatients | 1 | 2016 | 57 | 0.030 |
Why?
|
| Coculture Techniques | 2 | 2007 | 78 | 0.030 |
Why?
|
| Animals | 2 | 2007 | 8199 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2016 | 191 | 0.030 |
Why?
|
| Vidarabine | 1 | 2015 | 6 | 0.030 |
Why?
|
| Busulfan | 1 | 2015 | 6 | 0.030 |
Why?
|
| Aged, 80 and over | 2 | 2013 | 3900 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 2015 | 30 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2016 | 122 | 0.030 |
Why?
|
| Methotrexate | 1 | 2015 | 70 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2009 | 1233 | 0.030 |
Why?
|
| Idarubicin | 1 | 2013 | 8 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2013 | 12 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2018 | 2316 | 0.020 |
Why?
|
| Platelet Count | 1 | 2012 | 23 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 85 | 0.020 |
Why?
|
| Vinblastine | 1 | 2011 | 4 | 0.020 |
Why?
|
| Bleomycin | 1 | 2011 | 12 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2011 | 60 | 0.020 |
Why?
|
| Dacarbazine | 1 | 2011 | 31 | 0.020 |
Why?
|
| Disease Management | 1 | 2011 | 129 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 1179 | 0.020 |
Why?
|
| Vincristine | 1 | 2009 | 24 | 0.020 |
Why?
|
| Consensus | 1 | 2009 | 87 | 0.020 |
Why?
|
| Prednisone | 1 | 2009 | 69 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 238 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2009 | 153 | 0.020 |
Why?
|
| Cladribine | 1 | 2008 | 3 | 0.020 |
Why?
|
| Blast Crisis | 1 | 2008 | 4 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2008 | 23 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 471 | 0.020 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2008 | 11 | 0.020 |
Why?
|
| Leukemia, Myeloid | 1 | 2008 | 26 | 0.020 |
Why?
|
| Benzamides | 1 | 2008 | 60 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2008 | 32 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2008 | 45 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2008 | 68 | 0.020 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 42 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2009 | 267 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2009 | 484 | 0.020 |
Why?
|
| Antigens, CD34 | 1 | 2007 | 48 | 0.020 |
Why?
|
| Chemokine CXCL12 | 1 | 2007 | 27 | 0.020 |
Why?
|
| Culture Media | 1 | 2007 | 48 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2007 | 75 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2007 | 250 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 821 | 0.020 |
Why?
|
| Canada | 1 | 2005 | 63 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 155 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 729 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2007 | 603 | 0.010 |
Why?
|
| Cause of Death | 1 | 2005 | 236 | 0.010 |
Why?
|
| Patient Selection | 1 | 2003 | 272 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 1437 | 0.010 |
Why?
|
| United States | 1 | 2009 | 4072 | 0.010 |
Why?
|